TXG · 10x Genomics, Inc. · Stock research

Current Thesis

The post-print break recorded here on 2026-08-07 lasted one session. The −3.92% close at $45.60 on 2026-08-06 did put price under the $45.92 floor of the ten-close shelf built from 2026-07-21 to 2026-08-03, and the after-hours quote that evening was $43.99. above the prior record close of $49.43 set 2026-07-30. Market capitalisation $6.78B on 130.29M shares outstanding. The overnight fade was rejected; the guidance raise was repriced a day late.

The leg an investor is buying is narrow and now well specified. A single-cell franchise that did $598.7M in FY2025 (−2%) has a second platform with a demonstrated order book. On the 2026-08-06 call management said booked Atera orders "already greatly exceeded" the roughly 40 units planned for H2 2026 shipment, that manufacturing capacity rather than demand is the binding constraint, and that production expands "into 2027 and beyond." Atera lists at $495,000 with whole-transcriptome reagents around $2,200 per sample. Q2 revenue of $151.0M beat the roughly $146.8M consensus, GAAP EPS of −$0.14 beat −$0.24, and FY2026 guidance moved to $610–630M from the $600–625M range that had held since 2026-05-07.

What changed in the 24 hours after the print is the sell-side panel. The 16-analyst average target went from $41.54 on 2026-08-06 to $46.31 on 2026-08-08 (low $38, high $53). Citigroup raised to $50 while keeping Neutral and Morgan Stanley raised to $40 while keeping Equal-Weight, both on 2026-08-07; aggregated coverage of the same window reported TD Cowen to $47 from $25 and Stifel doubling to $50. Jefferies reiterated $53, Canaccord maintained $50 and Piper Sandler maintained $42 on 2026-08-07. The ratings distribution did not move: 5 Strong Buy, 1 Buy, 10 Hold, 0 Sell. Targets rose; conviction labels did not.

The unresolved item is timing, not demand. Q3 was guided to step down sequentially from $151.0M, Q4 to step up sharply, with the CFO saying Atera "accounts for the large majority of the Q4 sequential increase" and Atera's revenue contribution still framed to 2027. The FY range therefore rests on one quarter that has not happened and on a factory ramp that has no public unit count.

Narrative life-cycle: ACCELERATING. Dating it: a record close and a record intraday high on 2026-08-07 on 5.43M shares; the consensus target moving $4.77 in two sessions after twenty-one days without a confirmed raise; and the Atera order-book disclosure on 2026-08-06 being genuinely new information rather than a restatement. This supersedes the SATURATED label carried on 2026-08-07, which was dated to the 08-06 close and was contradicted by the following session. The counter-evidence is not gone — the $46.31 average target implies −10.99% from spot and 10 of 16 ratings remain Hold — but participation expanded rather than thinned.

Bullish and bearish views on 10x Genomics, Inc.

The model's bull view on 10x Genomics, Inc. (TXG), in brief: Booked Atera orders "already greatly exceeded" the ~40-unit H2 2026 shipment plan per management on the 2026-08-06 call, converting the platform from a launch story into an order-flow number, with capacity named as the constraint. The bear view: Price now sits above the published panel: the 2026-08-07 close of $52.03 against a $46.31 16-analyst average, a $53 high and a $38 low, with 10 of 16 ratings at Hold and no rating upgrades accompanying the target raises. Both cases follow in full.

Bull Case

• Booked Atera orders "already greatly exceeded" the ~40-unit H2 2026 shipment plan per management on the 2026-08-06 call, converting the platform from a launch story into an order-flow number, with capacity named as the constraint.
• Guidance moved up rather than held: FY2026 to $610–630M from $600–625M against roughly $613.9M consensus, framed as 2–5% growth excluding 2025's non-recurring settlement revenue.
• Consumables carried Q2 without instrument help: $130.8M of the $151.0M total, with spatial consumables $42.3M versus $36.4M a year earlier and single-cell consumables $88.5M, against $7.7M of instruments.
• Gross margin printed 74% in Q2 2026 versus 72% a year earlier, and 74% versus 67% on a comparison stripping settlement revenue from both periods.
• Balance sheet funds the capacity build without an announced raise: cash, cash equivalents and marketable securities $552.0M at 2026-06-30, up from roughly $523.4M at 2025-12-31 per the Q2 10-Q.
• The Proteintech Genomics acquisition, announced 2026-06-09 on undisclosed terms, closed within the quarter and adds high-plex protein panels already built on 10x Chromium Flex chemistry — a multiomics extension of the installed base rather than a new platform bet.

Bear Case

• Price now sits above the published panel: the 2026-08-07 close of $52.03 against a $46.31 16-analyst average, a $53 high and a $38 low, with 10 of 16 ratings at Hold and no rating upgrades accompanying the target raises.
• The quarter was a GAAP loss: operating loss $19.6M and net loss $17.9M in Q2 2026 versus operating income $30.1M and net income $34.5M in the prior-year period, which carried settlement revenue.
• Instruments contributed $7.7M of $151.0M. A capital-equipment narrative is being underwritten by consumables while the equipment line runs at a fraction of the total.
• FY2026 hangs on Q4. Q3 was guided to step down sequentially from $151.0M and no 2026 print settles Atera on the revenue line — only on order counts, shipment timing and margin.
• Funding backdrop is unfixed: the CEO described US academic and government conditions as tenuous with dollars still not flowing on 2026-08-06, and Bruker's Q2 on 2026-08-04 missed at $838.5M against roughly $853.6M consensus, attributing spatial-biology weakness to US academic budgets.
• A 52-week range of $11.16 to $52.22 means the entire re-rating is roughly twelve months old, and five-year beta of 2.04 means the name de-rates at about twice index amplitude in a tools risk-off.

Setup & Price Structure

The reference levels are dense and recent. Above: the 2026-08-07 intraday high $52.22 and close $52.03 are the record. Below, in order: $49.43 (prior record close, 2026-07-30); $45.92 (floor of the 2026-07-21→08-03 shelf and the approximate origin of the 08-07 gap); $45.60 (the 08-06 close that broke it); $43.22 (2026-07-20 close, the last print before the 07-21 breakout). The 50-day moving average read $37.05 on 2026-07-30, the most recent reading in this record and now materially stale; the distance from spot to any rising medium-term average is wide by any reading of that number.

Positioning observables, stated without a verdict. 14.16% of the 114.79M float and 4.58 days to cover per stockanalysis, with Benzinga computing 19.0% of float and 5.34 days on the same share count; no settlement covering the print has published yet. Retail-facing coverage clustered near the highs before the move: an overbought-RSI screen naming TXG on 2026-07-15 and an options whale-alert scan on 2026-07-09. Insider sales through mid-2026 ran under pre-arranged 10b5-1 plans (CEO plan adopted 2025-11-29, director plan 2026-03-13). Shares outstanding are 130.29M against a 114.79M float, and there is no announced offering. There is no earnings date inside the next 30 days — the Q2 10-Q for the period ended 2026-06-30 is already on file, which removes the disclosure event this note previously flagged for ~2026-08-10.

The structural read: 2026-08-07 was a gap-and-hold that reclaimed a broken shelf in one session. That kind of reversal leaves an unusually clean reference — the gap origin near $45.92 — and nothing between spot and it.

Catalyst Calendar (next 30 days)

• ~2026-08-11 (est.) — FINRA semi-monthly short-interest report covering the 2026-07-31 settlement. Shows whether the 16.25M-share short base covered into the late-July record closes or sat through them, which frames how much mechanical demand was still available going into the 2026-08-07 gap.
• ~2026-08-21 (est.) — practical close of the post-print revision window. The observable is whether any firm publishes a target above the $53 street high, or whether the panel settles with the average below spot.
• ~2026-08-26 (est.) — FINRA short-interest report covering the 2026-08-14 settlement. First positioning snapshot spanning both the 2026-08-06 print and the 2026-08-07 gap; separates covering from fresh shorting against a raised guide.
• ~2026-11-05 (est.) — Q3 2026 results. Outside the 30-day window but the only event that puts a number on the quarter guided to step down from $151.0M, and where the ~40-unit H2 shipment figure is confirmed or re-dated.

What Would Change Our Mind

The thing that breaks first is the 2026-08-07 gap. It was created in a single session with no intervening trade between $45.92 and the opening print, so a full retracement erases the entire post-print repricing and returns the chart to the shelf it lost on 08-06. Concretely: a weekly close below $45.92 puts price back under the floor of the 2026-07-21→08-03 range and would date the ACCELERATING label as a two-week phenomenon.

On fundamentals, three things would flip the read independent of price. First, the ~40-unit H2 2026 Atera shipment plan being cut or re-dated into 2027 at the Q3 report — the order book only matters if it converts on the guided schedule. Second, FY2026 guidance being narrowed downward or returned below the $610M floor, which would mean the Q4 step-up did not arrive. Third, Q3 gross margin printing below the mid-60s full-year framing, which would reframe the Q2 74% as a tariff-refund artefact ($2.6M) rather than a run-rate.

What would confirm rather than break it: a target published above $53, a short-interest print showing the base intact rather than covered, or a named Atera unit count in Q3 disclosure.

Correlation Notes

• Life-science tools trade as a basket on academic and pharma budget news. Bruker's 2026-08-04 Q2 miss ($838.5M versus roughly $853.6M consensus, organic growth 2.8%, FY revenue narrowed to $3.54–3.57B) was attributed to US academic and government funding, and Illumina's FY2026 range of $4.60–4.64B is the other sector anchor — Illumina's 2026-07-30 guide raise preceded TXG's prior record close on the same date.
• Five-year beta 2.04. In a broad risk-off, the name that gained the most in the basket is the one that gives back fastest; in a funding-relief rally it leads.
• NIH and US federal research appropriations are the shared upstream variable for TXG, Bruker, Illumina, Pacific Biosciences and Standard BioTools. A continuing-resolution outcome or an NIH budget headline moves the group together regardless of company-specific order books.
• The Atera leg is idiosyncratic and partially decouples TXG from the group: it is a capacity story inside a flat-to-down sector, so instrument-cycle read-throughs from peers are a weaker guide to TXG than they were before 2026-08-06.